CircATXN7 accelerated the malignancy of NSCLC cells through adsorbing miR-7-5p and upregulating PFN2, offering evidence to support circATXN7 as a target for NSCLC treatment.
Downregulation of circATXN7 represses non-small cell lung cancer growth by releasing miR-7-5p.